Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

86%

6 trials in Phase 3/4

Results Transparency

71%

5 of 7 completed trials have results

Key Signals

5 with results

Enrollment Performance

Analytics

Phase 3

4(57.1%)

Phase 4

2(28.6%)

Phase 2

1(14.3%)

7Total

Phase 3(4)

Phase 4(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT06437626Phase 3Completed

Efficacy and Safety of Mexidol® in Stroke Therapy

Role: lead

NCT06903156Phase 2Completed

Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)

Role: lead

NCT06437639Phase 4Completed

MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Role: lead

NCT06834490Phase 3Completed

Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia

Role: lead

NCT06854601Phase 3Completed

Safety and Efficacy of Mexidol® for ADHD in Children Aged 6-12

Role: lead

NCT06221826Phase 4Completed

MEXIDOL® in the Rehabilitation Treatment of Patients With Acute Cerebral Failure

Role: lead

NCT02793687Phase 3Completed

Study of Efficacy and Safety of MEXIDOL® in Ischemic Stroke Therapy

Role: lead

All 7 trials loaded